Targeted therapy for metastatic non–small cell lung cancer Conference Paper
| Author: | Riely, G. J. |
| Title: | Targeted therapy for metastatic non–small cell lung cancer |
| Conference Title: | NCCN 2023 Annual Conference |
| Abstract: | The use of next-generation tyrosine kinase inhibitors has led to improved progression-free survival for patients with metastatic non–small cell lung cancer (NSCLC) and those with EGFR-mutant and ALK-positive tumors. Newer therapeutics can now target KRAS G12C mutations, EGFR exon 20 insertions, and ERBB2 (HER2) mutations. Patients with metastatic NSCLC should undergo molecular testing for these mutations as well as for BRAF mutations; MET exon 14 skipping alterations; and ROS1, RET, and NTRK gene rearrangements (fusions). Novel targeted therapeutics are emerging at a fast pace. © JNCCN—Journal of the National Comprehensive Cancer Network. |
| Keywords: | immunohistochemistry; gene mutation; exon; conference paper; biological marker; epidermal growth factor receptor; epidermal growth factor receptor 2; gene rearrangement; k ras protein; b raf kinase; epidermal growth factor receptor kinase inhibitor; scatter factor receptor; non small cell lung cancer; oncogene ret; first-line treatment; immune checkpoint inhibitor; high throughput sequencing; human; anaplastic lymphoma kinase inhibitor |
| Journal Title | Journal of the National Comprehensive Cancer Network |
| Volume: | 21 |
| Issue: | 5.5 |
| Conference Dates: | 2023 Mar 31-Apr 2 |
| Conference Location: | Orlando, FL |
| ISBN: | 1540-1405 |
| Publisher: | Harborside Press |
| Date Published: | 2023-06-01 |
| Start Page: | 559 |
| End Page: | 562 |
| Language: | English |
| DOI: | 10.6004/jnccn.2023.5009 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Conference paper -- Meeting also available virtually -- Source: Scopus |
